Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

128.93
+0.93000.73%
Pre-market: 129.200.2700+0.21%08:43 EDT
Volume:1.13M
Turnover:145.74M
Market Cap:18.90B
PE:12.33
High:131.10
Open:128.47
Low:128.25
Close:128.00
52wk High:207.59
52wk Low:110.04
Shares:146.61M
Float Shares:146.22M
Volume Ratio:0.80
T/O Rate:0.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):10.45
EPS(LYR):11.21
ROE:9.13%
ROA:5.62%
PB:1.07
PE(LYR):11.50

Loading ...

Biogen Inc. Expects $46 Million Charge to Impact Q2 2025 EPS by ($0.26) Due to In-Process R&D Expenses

Reuters
·
Jul 08

Biogen (BIIB) Receives a Buy from RBC Capital

TIPRANKS
·
Jul 08

RBC Trims Price Target on Biogen to $208 From $213, Keeps Outperform Rating

MT Newswires Live
·
Jul 07

Biogen’s Litifilimab Study: A Long-Term Look at SLE Treatment

TIPRANKS
·
Jul 04

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
Jul 02

BUZZ - Nasdaq top and bottom performing stocks at about 02:45 p.m. EDT on 2025-07-01

Reuters
·
Jul 02

Biogen’s Felzartamab Study: A Potential Game-Changer for Kidney Transplant Recipients

TIPRANKS
·
Jul 02

Biogen Begins Phase 3 Trial of Felzartamab for Rare Kidney Disease

MT Newswires Live
·
Jun 30

Biogen Initiates Phase 3 Clinical Trial of Felzartamab for Primary Membranous Nephropathy Treatment

Reuters
·
Jun 30

BRIEF-Biogen Says Higher Dose Nusinersen Is Consistent With Known Safety Profile 12 Mg Spinraza

Reuters
·
Jun 27

Biogen Inc. Awaits Regulatory Review for Higher Dose Regimen of Nusinersen in Global Markets

Reuters
·
Jun 27

Biogen Price Target Maintained With a $213.00/Share by RBC Capital

Dow Jones
·
Jun 27

Biogen's Leqembi Has 'Meaningful Advantages' Over Lilly's Kisunla, Leading to Potential Billions in Sales, RBC Says

MT Newswires Live
·
Jun 27

Biogen’s New Study on Omaveloxolone: Implications for Investors

TIPRANKS
·
Jun 27

Salanersen presents long-term upside opportunity for Biogen, says Morgan Stanley

TIPRANKS
·
Jun 26

BUZZ-U.S. STOCKS ON THE MOVE-Coinbase, Rubrik, AeroVironment

Reuters
·
Jun 26

Biogen Is Maintained at Outperform by RBC Capital

Dow Jones
·
Jun 25

BUZZ-U.S. STOCKS ON THE MOVE-Array Technologies, Viking Therapeutics, Winnebago

Reuters
·
Jun 25

Biogen price target raised to $213 from $205 at RBC Capital

TIPRANKS
·
Jun 25

BUZZ-RBC raises Biogen's price target as pipeline prospects come into focus

Reuters
·
Jun 25